Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 1/20 | 0.54 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | BMX | P51813 | 1/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242231 | 0.86 | EGFR (0.52) | AURKASYK | |
| SCHEMBL4237476 | 0.81 | AURKA (1.00) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL3694508 | 0.81 | AURKA (1.00) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL13777946 | 0.71 | AURKA (1.00) | AURKALCKIGF1REIF2AK2SYK | |
| Anilinopyrimidine1 SCHEMBL676556 | 0.71 | AURKA (1.00) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL4237478 | 0.70 | AURKA (0.85) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL3694510 | 0.70 | AURKA (0.85) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL27981675 | 0.70 | AURKA (0.69) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL20097955 | 0.69 | AURKA (0.77) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL4239038 | 0.68 | AURKA (0.70) | AURKASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216782-B2 | PTTG1 as a biomarker for cancer treatment | CEDARS-SINAI MEDICAL CENTER (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110281935-A1 | Combination Therapy Based on SRC and Aurora Kinase Inhibition for the Treatment of Cancer | THE INSTITUTE FOR CANCER RESEARCH | 2011-11-17 | — | — | US | disclosed |
| US-20110009473-A1 | PTTG1 AS A BIOMARKER FOR CANCER TREATMENT | CEDARS-SINAI MEDICAL CENTER (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2250290-A2 | PTTG1 AS A BIOMARKER FOR CANCER TREATMENT | Cedars-Sinai Medical Center (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009114817-A2 | PTTG1 AS A BIOMARKER FOR CANCER TREATMENT | CEDARS-SINAI MEDICAL CENTER (US) | 2009-09-17 | — | — | WO | disclosed |